These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11561684)

  • 1. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
    Vogelzang NJ; Aklilu M; Stadler WM; Dumas MC; Mikulski SM
    Invest New Drugs; 2001; 19(3):255-60. PubMed ID: 11561684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
    Mikulski SM; Costanzi JJ; Vogelzang NJ; McCachren S; Taub RN; Chun H; Mittelman A; Panella T; Puccio C; Fine R; Shogen K
    J Clin Oncol; 2002 Jan; 20(1):274-81. PubMed ID: 11773179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.
    Pavlakis N; Vogelzang NJ
    Expert Opin Biol Ther; 2006 Apr; 6(4):391-9. PubMed ID: 16548765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell.
    Drugs R D; 2007; 8(2):120-4. PubMed ID: 17324010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
    Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
    Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.
    Costanzi J; Sidransky D; Navon A; Goldsweig H
    Cancer Invest; 2005; 23(7):643-50. PubMed ID: 16305992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.
    Drucker B; Bacik J; Ginsberg M; Marion S; Russo P; Mazumdar M; Motzer R
    Invest New Drugs; 2003 Aug; 21(3):341-5. PubMed ID: 14578682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Onconase: a ribonuclease with antitumor activity].
    Zwolińska M; Smolewski P
    Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ
    J Clin Oncol; 2015 May; 33(13):1430-7. PubMed ID: 25452452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regional immunotherapy of metastatic renal cell carcinoma].
    Heinzer H; Huland E; Huland H
    Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
    Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
    J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
    Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
    Amato R; Zhai J; Willis J; Saxena S; DeFoe M
    Clin Genitourin Cancer; 2012 Sep; 10(3):153-8. PubMed ID: 22551785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
    Beck AK; Pass HI; Carbone M; Yang H
    Future Oncol; 2008 Jun; 4(3):341-9. PubMed ID: 18518759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.